ITMCTR2100004763招募中1 期
Human pharmacokinetic study of Guhong injection
Shanghai Institute of Materia Medica, CAS; Second Affilitated Hospital of Tianjin University of TCM0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 35（—）
- 性别
- All
入选标准
- •1. Aged between 18 and 35 years.
- •2. The weight of all subjects must be greater than 50 kg, and the body mass index should not exceed 15% of the ideal value. Body mass index = weight (kg)/height (m) squared (body mass index is between 19 and 24).
- •3. General physical examination, laboratory, physical and chemical examinations are all normal.
- •4. The subject agreed to inform them to eat food and medicine within 1 week.
- •5. According to GCP regulations, obtain informed consent and take the test voluntarily.
排除标准
- •1. Subjects who had primary disease in key organs including heart, liver and kidneys, or had a history of gastrointestinal disease, metabolic disease or neurological disease.
- •2. Subjects who had mental or physical disability, or subjects with a history of lunacy.
- •3. Subjects with clinically significant abnormalities in physical examination, biochemistry, blood and urine analysis, electrocardiography, chest X-ray, or ultrasound screening.
- •4. Subjects with a history of drug dependence, drug abuse or alcoholism.
- •5. Subjects with physical allergy or known allergic to Honghua, Guhong ingredients and product (including other drugs).
- •6. Subjects who took herbal medicines or food or beverage containing Honghua or aceglutamide.
- •7. Subjects who participated any other investigational drug study within four week prior to this study.
- •8. Subjects who took any medication with known damaging effects on main organs within three months prior to this study, or took any over-the-counter or prescription drugs within two week prior to this study.
- •9. Subjects with hemorrhagic tendency.
- •10. Menstrual, pregnant or breast-feeding women and women at childbearing age take oral contraceptive.
- •11. Subjects with abnormal vital signs (systolic blood pressure <90 mmHg or >140 mmHg, or diastolic blood pressure < 50 mmHg or > 90 mmHg, or heart rate < 50 bpm or >100 bpm).
- •12. Subjects who frequently took alcohol with six months (i.e., more than 14 Units of alcohol every week) or took more than one cigarette every day with three months prior to this study.
- •13. Subjects who took any soft drugs (e.g., marijuana) with three month or took any hard drugs (e.g., cocaine, phencyclidine, etc) with one year prior to this study.
- •14. Subjects with risk factors that possibly influence the absorption, disposition, excretion and metabolism.
- •15. Subjects who donate blood within three month prior to this study.
- •16. In the opinion of the investigator, subjects who are not suitable to participate in the study for whatever reasons must be excluded.
研究者
相似试验
已完成
不适用
The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trialDiseases of the ear and mastoid processKCT0001381Yuyu Phama60
尚未招募
不适用
Cow milk injection in internal hemorrhoidsCTRI/2019/11/022051Dr Gajanan Dhele
尚未招募
不适用
Pharmacokinetics of single-dose administration of paracetamol by nasoduodenal tube throughout childhoodPainPijn of koorts waarbij paracetamol gegeven wordt via de duodenale sonde bij kinderenfeverNL-OMON45360Erasmus MC, Universitair Medisch Centrum Rotterdam20
进行中（未招募）
不适用
A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s LymphomaT-cell or B-cell precursor (BCP) acute lymphoblastic leukaemia (T-ALL or BCP-ALL) or T-cell Non Hodgkin’s lymphoma (T-NHL)MedDRA version: 9.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaMedDRA version: 9.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellEUCTR2008-002219-42-CZMundipharma Research Limited28
进行中（未招募）
不适用
A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin’s LymphomaEUCTR2008-002219-42-ATMundipharma Research Limited28